HAE Biology and the Bradykinin Cascade

Hereditary angioedema (HAE) is a rare, potentially life-threatening condition driven by dysregulated bradykinin production — most commonly resulting from mutations in the SERPING1 gene, which encodes the C1-inhibitor protein. When C1-inhibitor function is absent or deficient, the contact activation pathway runs unchecked, generating excess bradykinin that causes episodes of severe subcutaneous and submucosal swelling. These attacks can affect the face, extremities, gastrointestinal tract, and — most dangerously — the larynx, where untreated episodes carry a real risk of asphyxiation.

The bradykinin cascade is initiated when factor XII (Hageman factor) is activated on negatively charged surfaces, triggering a series of proteolytic events that ultimately convert prekallikrein — encoded by KLKB1 — into active plasma kallikrein. Kallikrein then cleaves high-molecular-weight kininogen (HMWK) to release bradykinin, which binds B2 receptors on vascular endothelium, driving the vasodilation and vascular permeability that underlie HAE attacks. In C1-inhibitor-deficient patients, this loop is self-amplifying and poorly regulated, making the kallikrein step a compelling chokepoint for therapeutic intervention.

Current standard-of-care for HAE spans acute treatments — such as plasma-derived C1-inhibitor concentrate, icatibant (a bradykinin B2 receptor antagonist), and ecallantide (a kallikrein inhibitor) — and long-term prophylaxis options including subcutaneous lanadelumab (a monoclonal antibody against plasma kallikrein) and oral berotralstat. While these therapies have meaningfully improved patient outcomes, none addresses the underlying genetic defect, and all require ongoing administration. The appeal of a durable, potentially one-time gene editing intervention is therefore substantial, both clinically and commercially.

Why KLKB1 Is the Right Target for CRISPR Gene Editing in HAE

KLKB1 — the gene encoding plasma kallikrein — is the mechanistically optimal target for a gene-silencing approach to HAE because it sits upstream of bradykinin generation and is predominantly expressed in the liver, the natural destination tissue for lipid nanoparticle (LNP)-mediated delivery. Silencing or permanently reducing the expression of KLKB1 in hepatocytes would be expected to blunt kallikrein activity system-wide, reducing the substrate available for bradykinin production regardless of whether C1-inhibitor is functional.

The liver-targeting logic is critical. Unlike ex vivo gene editing approaches — which require harvesting patient cells, editing them in a laboratory, and reinfusing them — in vivo CRISPR strategies rely on the liver’s natural affinity for LNP uptake via apolipoprotein E-mediated endocytosis. This makes hepatocyte-expressed genes like KLKB1 particularly tractable for in vivo editing without the logistical and manufacturing complexity of cell therapy. According to ClinicalTrials.gov, NTLA-2002 has been evaluated in a Phase I/II study (NCT05120830), with the HAELO Phase III programme as the successor.

Targeting KLKB1 rather than attempting to restore SERPING1 function (C1-inhibitor gene replacement) offers a complementary mechanistic rationale: rather than restoring a deficient inhibitor, the approach reduces the substrate enzyme that the inhibitor would otherwise regulate. This substrate-reduction strategy has precedent in rare disease — most notably in transthyretin amyloidosis, where RNA interference targeting TTR liver expression (patisiran, vutrisiran) has demonstrated durable efficacy. CRISPR-based editing of KLKB1 takes this logic further by aiming for permanent genomic modification rather than repeated dosing of gene-silencing agents, as documented in research published by the New England Journal of Medicine.

“Rather than restoring a deficient inhibitor, the KLKB1 editing approach reduces the substrate enzyme itself — a substrate-reduction strategy that aims for permanent genomic modification rather than repeated dosing.”

How NTLA-2002 (Lonvo-Z) Works: Delivery and Editing Mechanism

NTLA-2002 (Lonvo-Z) is a CRISPR-Cas9 in vivo gene editing candidate developed by Intellia Therapeutics that targets the KLKB1 gene in hepatocytes via systemic lipid nanoparticle delivery. The construct packages mRNA encoding the Cas9 nuclease together with a guide RNA (gRNA) specific to a KLKB1 exonic sequence, formulated within an LNP optimised for hepatic uptake. Once endocytosed by liver cells, the LNP releases its cargo, the Cas9 is translated, assembles with the gRNA, and creates a double-strand break at the target locus. Imprecise repair via non-homologous end joining (NHEJ) introduces insertions or deletions (indels) that disrupt the KLKB1 reading frame, permanently reducing kallikrein expression.

The key distinction of in vivo CRISPR editing versus the ex vivo paradigm (as exemplified by approved sickle cell disease therapies) is that no cell extraction, ex vivo manipulation, or conditioning regimen is required. The patient receives an intravenous infusion of the LNP formulation, and editing occurs in situ within the liver. This dramatically reduces the complexity and cost of the therapeutic process and, in principle, makes the treatment accessible in outpatient or day-clinic settings — a significant advantage for a disease like HAE where patients may be geographically distributed and where the current prophylaxis burden already requires frequent clinic visits or self-injection.

The safety profile of in vivo CRISPR editing via LNPs has been a central focus of clinical evaluation. Key considerations include off-target editing at non-KLKB1 genomic loci, innate immune responses to LNP components (particularly ionisable lipids), and the theoretical risk of Cas9 immunogenicity following systemic delivery. The Phase I/II programme registered as NCT05120830 was designed to characterise these parameters alongside the primary efficacy readout of kallikrein activity reduction and HAE attack frequency.

Clinical Development Pathway: From Phase I to HAELO Phase III

The clinical development of NTLA-2002 follows a staged translational path that began with a Phase I/II dose-escalation study registered under ClinicalTrials.gov identifier NCT05120830. Data from this study — which evaluated safety, tolerability, pharmacodynamics (kallikrein activity reduction), and preliminary efficacy (HAE attack rate) — were published in the New England Journal of Medicine, one of the highest-impact venues for clinical trial data and a strong signal of the scientific community’s interest in this programme.

The HAELO Phase III study represents the pivotal evaluation designed to support a regulatory submission. Phase III HAE trials typically enrol patients with documented HAE type I or II (SERPING1 mutation-confirmed), randomise them to active treatment versus placebo, and measure the primary endpoint of HAE attack rate over a defined observation period — commonly 26 or 52 weeks. For a gene editing therapy, the durability of effect beyond the primary endpoint window is a critical secondary consideration, as regulators and payers will want evidence that the editing event is stable and that kallikrein suppression is maintained over multi-year follow-up.

Regulatory interactions for NTLA-2002 would be expected to include FDA Breakthrough Therapy or Regenerative Medicine Advanced Therapy (RMAT) designation, given the unmet need in HAE and the novelty of the in vivo CRISPR modality. Intellia’s SEC filings — including 10-K annual reports and 8-K current reports — are the primary public sources for confirmed regulatory status, PDUFA date assignments, and Phase III enrolment progress. According to the FDA, RMAT designation is available for regenerative medicine therapies addressing serious conditions with preliminary clinical evidence of substantial improvement over existing therapies.

The ASH (American Society of Hematology), ACAAI (American College of Allergy, Asthma and Immunology), and HAEi (HAE International) conference proceedings are the key venues where interim and final HAELO data are expected to be presented ahead of or alongside peer-reviewed publication. Monitoring these venues — alongside Intellia’s press release cadence — is essential for timely intelligence on Phase III readouts.

IP and Competitive Landscape for CRISPR HAE Therapies

The intellectual property landscape surrounding in vivo CRISPR gene editing for HAE spans three intersecting domains: foundational CRISPR-Cas9 platform patents, liver-targeted LNP delivery IP, and disease-specific therapeutic claims covering KLKB1 knockdown in HAE. Intellia Therapeutics holds a significant IP position in in vivo CRISPR liver editing, built on licences from foundational CRISPR patent estates and its own proprietary LNP formulation and guide RNA design filings.

Three search dimensions were identified as critical for a comprehensive IP intelligence product on this topic: (1) core mechanism patents covering CRISPR-Cas9 in vivo gene editing, KLKB1 knockdown, and LNP delivery; (2) disease-specific clinical target filings covering NTLA-2002/Lonvo-Z, Phase III HAE, FDA submissions, and kallikrein pathway therapeutic interventions; and (3) assignee and combination landscape analysis covering Intellia Therapeutics IP filings, combination prophylaxis strategies, and competitive CRISPR HAE pipeline. These dimensions map directly to the freedom-to-operate, patentability, and competitive positioning questions most relevant to IP professionals and R&D leaders evaluating this space.

The competitive pipeline for HAE gene therapy extends beyond CRISPR. RNA interference approaches — building on the established precedent of givosiran (targeting ALAS1 in acute hepatic porphyria) and inclisiran (targeting PCSK9 in hypercholesterolaemia) — have been explored for HAE-relevant targets. However, CRISPR-based permanent editing represents a differentiated modality that, if validated by HAELO Phase III data, could command a distinct IP and commercial position. According to WIPO, gene editing patent filings have grown substantially in recent years, with liver-targeted in vivo delivery representing one of the most active sub-domains. For a comprehensive freedom-to-operate analysis, PatSnap’s life sciences intelligence platform provides access to the full global patent estate across all three IP dimensions.

Combination prophylaxis strategies — pairing a gene editing intervention with existing kallikrein inhibitors or C1-inhibitor replacement during the period before full editing effect is established — also represent an active area of IP and clinical protocol development. These combination claims, if filed and granted, could extend the commercial lifecycle of NTLA-2002 beyond the initial monotherapy indication. IP professionals monitoring this space should track Intellia’s PCT and national phase filings, as well as any collaborative IP arising from academic or clinical partnerships disclosed in Intellia’s SEC filings and investor relations communications.